Clinical Trials Browser

INDUSTRY × Afatinib × Tumor-Agnostic × Clear all

NCT00748709 2025-02-11

Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.

Phase 2 Terminated

20 enrolled 11 charts

Neoplasms

NCT01214616 2025-02-07

BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours

Phase 1 Completed

17 enrolled 15 charts

Neoplasms

NCT02171650 2025-01-23

BIBW 2992 in Patients With Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT01206816 2019-02-01

An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours

Phase 1 Completed

57 enrolled 19 charts

Neoplasms

NCT02020577 2017-06-22

Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours

Phase 1 Completed

58 enrolled 13 charts

Neoplasms

NCT00809133 2016-03-14

Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours

Phase 1 Completed

83 enrolled 42 charts

Neoplasms

NCT02171663 2015-01-28

Dose Escalation Study of BIBW 2992 in Patients With Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT02171637 2014-06-24

Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT02171676 2014-06-24

BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT02171702 2014-06-24

Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumours

Phase 1 Completed

Neoplasms

NCT02171728 2014-06-24

Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT02171741 2014-06-24

Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT01169675 2014-06-09

BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid Tumours

Phase 1 Completed

53 enrolled 15 charts

Neoplasms

NCT00875433 2013-12-30

Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours

Phase 2 Completed

60 enrolled 26 charts

Neoplasms

NCT00730821 2009-08-21

Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors

Phase 1 Completed

Neoplasms